Amelioration of sepsis by inhibiting sialidase-mediated disruption of the CD24-SiglecG interaction

Guo Yun Chen, Xi Chen, Samantha King, Karen A. Cavassani, Jiansong Cheng, Xincheng Zheng, Hongzhi Cao, Hai Yu, Jingyao Qu, Dexing Fang, Wei Wu, Xue Feng Bai, Jin Qing Liu, Shireen A. Woodiga, Chong Chen, Lei Sun, Cory M. Hogaboam, Steven L. Kunkel, Pan Zheng, Yang Liu

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

Suppression of inflammation is critical for effective therapy of many infectious diseases. However, the high rates of mortality caused by sepsis attest to the need to better understand the basis of the inflammatory sequelae of sepsis and to develop new options for its treatment. In mice, inflammatory responses to host danger-associated molecular patterns (DAMPs), but not to microbial pathogen-associated molecular patterns (PAMPs), are repressed by the t interaction of CD24 and SiglecG (SIGLEC10 in human). Here we use an intestinal perforation model of sepsis to show that microbial sialidases target the sialic acid-based recognition of CD24 by SiglecG/10 to exacerbate inflammation. Sialidase inhibitors protect mice against sepsis by a mechanism involving both CD24 and Siglecg, whereas mutation of either gene exacerbates sepsis. Analysis of sialidase-deficient bacterial mutants confirms the key contribution of disrupting sialic acid-based pattern recognition to microbial virulence and supports the clinical potential of sialidase inhibition for dampening inflammation caused by infection.

Original languageEnglish (US)
Pages (from-to)428-435
Number of pages8
JournalNature Biotechnology
Volume29
Issue number5
DOIs
StatePublished - May 2011

Fingerprint

Neuraminidase
Sepsis
N-Acetylneuraminic Acid
Acids
Pathogens
Pattern recognition
Inflammation
Genes
Intestinal Perforation
Communicable Diseases
Virulence
Mutation
Mortality
Infection

ASJC Scopus subject areas

  • Applied Microbiology and Biotechnology
  • Biotechnology
  • Molecular Medicine
  • Bioengineering
  • Biomedical Engineering

Cite this

Amelioration of sepsis by inhibiting sialidase-mediated disruption of the CD24-SiglecG interaction. / Chen, Guo Yun; Chen, Xi; King, Samantha; Cavassani, Karen A.; Cheng, Jiansong; Zheng, Xincheng; Cao, Hongzhi; Yu, Hai; Qu, Jingyao; Fang, Dexing; Wu, Wei; Bai, Xue Feng; Liu, Jin Qing; Woodiga, Shireen A.; Chen, Chong; Sun, Lei; Hogaboam, Cory M.; Kunkel, Steven L.; Zheng, Pan; Liu, Yang.

In: Nature Biotechnology, Vol. 29, No. 5, 05.2011, p. 428-435.

Research output: Contribution to journalArticle

Chen, GY, Chen, X, King, S, Cavassani, KA, Cheng, J, Zheng, X, Cao, H, Yu, H, Qu, J, Fang, D, Wu, W, Bai, XF, Liu, JQ, Woodiga, SA, Chen, C, Sun, L, Hogaboam, CM, Kunkel, SL, Zheng, P & Liu, Y 2011, 'Amelioration of sepsis by inhibiting sialidase-mediated disruption of the CD24-SiglecG interaction', Nature Biotechnology, vol. 29, no. 5, pp. 428-435. https://doi.org/10.1038/nbt.1846
Chen, Guo Yun ; Chen, Xi ; King, Samantha ; Cavassani, Karen A. ; Cheng, Jiansong ; Zheng, Xincheng ; Cao, Hongzhi ; Yu, Hai ; Qu, Jingyao ; Fang, Dexing ; Wu, Wei ; Bai, Xue Feng ; Liu, Jin Qing ; Woodiga, Shireen A. ; Chen, Chong ; Sun, Lei ; Hogaboam, Cory M. ; Kunkel, Steven L. ; Zheng, Pan ; Liu, Yang. / Amelioration of sepsis by inhibiting sialidase-mediated disruption of the CD24-SiglecG interaction. In: Nature Biotechnology. 2011 ; Vol. 29, No. 5. pp. 428-435.
@article{dbc1dbd36bd444e6a31a398f55cfc5fd,
title = "Amelioration of sepsis by inhibiting sialidase-mediated disruption of the CD24-SiglecG interaction",
abstract = "Suppression of inflammation is critical for effective therapy of many infectious diseases. However, the high rates of mortality caused by sepsis attest to the need to better understand the basis of the inflammatory sequelae of sepsis and to develop new options for its treatment. In mice, inflammatory responses to host danger-associated molecular patterns (DAMPs), but not to microbial pathogen-associated molecular patterns (PAMPs), are repressed by the t interaction of CD24 and SiglecG (SIGLEC10 in human). Here we use an intestinal perforation model of sepsis to show that microbial sialidases target the sialic acid-based recognition of CD24 by SiglecG/10 to exacerbate inflammation. Sialidase inhibitors protect mice against sepsis by a mechanism involving both CD24 and Siglecg, whereas mutation of either gene exacerbates sepsis. Analysis of sialidase-deficient bacterial mutants confirms the key contribution of disrupting sialic acid-based pattern recognition to microbial virulence and supports the clinical potential of sialidase inhibition for dampening inflammation caused by infection.",
author = "Chen, {Guo Yun} and Xi Chen and Samantha King and Cavassani, {Karen A.} and Jiansong Cheng and Xincheng Zheng and Hongzhi Cao and Hai Yu and Jingyao Qu and Dexing Fang and Wei Wu and Bai, {Xue Feng} and Liu, {Jin Qing} and Woodiga, {Shireen A.} and Chong Chen and Lei Sun and Hogaboam, {Cory M.} and Kunkel, {Steven L.} and Pan Zheng and Yang Liu",
year = "2011",
month = "5",
doi = "10.1038/nbt.1846",
language = "English (US)",
volume = "29",
pages = "428--435",
journal = "Biotechnology",
issn = "1087-0156",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Amelioration of sepsis by inhibiting sialidase-mediated disruption of the CD24-SiglecG interaction

AU - Chen, Guo Yun

AU - Chen, Xi

AU - King, Samantha

AU - Cavassani, Karen A.

AU - Cheng, Jiansong

AU - Zheng, Xincheng

AU - Cao, Hongzhi

AU - Yu, Hai

AU - Qu, Jingyao

AU - Fang, Dexing

AU - Wu, Wei

AU - Bai, Xue Feng

AU - Liu, Jin Qing

AU - Woodiga, Shireen A.

AU - Chen, Chong

AU - Sun, Lei

AU - Hogaboam, Cory M.

AU - Kunkel, Steven L.

AU - Zheng, Pan

AU - Liu, Yang

PY - 2011/5

Y1 - 2011/5

N2 - Suppression of inflammation is critical for effective therapy of many infectious diseases. However, the high rates of mortality caused by sepsis attest to the need to better understand the basis of the inflammatory sequelae of sepsis and to develop new options for its treatment. In mice, inflammatory responses to host danger-associated molecular patterns (DAMPs), but not to microbial pathogen-associated molecular patterns (PAMPs), are repressed by the t interaction of CD24 and SiglecG (SIGLEC10 in human). Here we use an intestinal perforation model of sepsis to show that microbial sialidases target the sialic acid-based recognition of CD24 by SiglecG/10 to exacerbate inflammation. Sialidase inhibitors protect mice against sepsis by a mechanism involving both CD24 and Siglecg, whereas mutation of either gene exacerbates sepsis. Analysis of sialidase-deficient bacterial mutants confirms the key contribution of disrupting sialic acid-based pattern recognition to microbial virulence and supports the clinical potential of sialidase inhibition for dampening inflammation caused by infection.

AB - Suppression of inflammation is critical for effective therapy of many infectious diseases. However, the high rates of mortality caused by sepsis attest to the need to better understand the basis of the inflammatory sequelae of sepsis and to develop new options for its treatment. In mice, inflammatory responses to host danger-associated molecular patterns (DAMPs), but not to microbial pathogen-associated molecular patterns (PAMPs), are repressed by the t interaction of CD24 and SiglecG (SIGLEC10 in human). Here we use an intestinal perforation model of sepsis to show that microbial sialidases target the sialic acid-based recognition of CD24 by SiglecG/10 to exacerbate inflammation. Sialidase inhibitors protect mice against sepsis by a mechanism involving both CD24 and Siglecg, whereas mutation of either gene exacerbates sepsis. Analysis of sialidase-deficient bacterial mutants confirms the key contribution of disrupting sialic acid-based pattern recognition to microbial virulence and supports the clinical potential of sialidase inhibition for dampening inflammation caused by infection.

UR - http://www.scopus.com/inward/record.url?scp=79955777060&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955777060&partnerID=8YFLogxK

U2 - 10.1038/nbt.1846

DO - 10.1038/nbt.1846

M3 - Article

VL - 29

SP - 428

EP - 435

JO - Biotechnology

JF - Biotechnology

SN - 1087-0156

IS - 5

ER -